Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, June 14, 2024

EarlyExo: Effects of Atalante X exoskeleton on gait recovery in non- or poorly ambulatory patients with hemiparesis in the acute/subacute phase

This had better get you 100% walking recovery in the hospital, it'll never be able to be used outside the clinic.

Functional Ambulation Categories (FAC) is a 6-point functional walking test. I guess I'm a 5.

Scoring and Score Interpretation[2]:

 

 EarlyExo: Effects of Atalante X exoskeleton on gait recovery in non- or poorly ambulatory patients with hemiparesis in the acute/subacute phase

M. Steinböck 1 , A. Buetikofer 1 , L. M. Huber 1 , K. Jahn 1,2 , F. Müller 1 1 Schoen Clinic Bad Aibling, Department of Neurology, Research Group, Bad Aibling, Germany 2 German Center for Vertigo and Balance Disorders (DSGZ), Ludwig-Maximilians University of Munich, Germany 
 
Background: 
 
According to recent studies approximately 30 % of stroke survivors experience significant disability lasting beyond one month following their stroke [1]. This prolonged disability not only contributes to extended hospital stays but also poses challenges in returning home and resuming work activities, thereby incurring substantial financial burdens [2]. --is acknowledged to enhance overall recovery [3, 4]. Numerous robotic aids designed for physiotherapeutic neurological rehabilitation are available on the mar- ket, one of them being motorized exoskeletons. These devices comprise orthoses attached to limbs, offering motorized assistance during walking. The Atalante X exoskeleton (Wandercraft, France) allows individuals with significant walking impairments to stand and walk without hands support. Its functionalities extend to facilitating strength and balance exercises. Previous research has shown that robotic-supported gait therapy effectively assists post-stroke patients in regaining their ability to walk [5, 6, 7]. The interventional, international and multicentre study EarlyExo is a prospective randomized controlled trial (RCT), which investigates the therapeutic efficacy of Atalante X gait therapy. Its focus lies on non- or poorly ambulatory stroke patients experiencing hemiparesis during the acute/subacute phase, particularly within one to four months post-stroke. 
 
Methods: 
 
In the acute/subacute phase following a stroke, patients with hemiparesis and a Functional Ambulation Category (FAC) value below 2 are eligible for participation. The FAC is a 6-point scale assessing walking ability based on required physical support or supervision. Below FAC 2 identifies individuals in need of continuous manual assistance for mobility. Patients are enrolled across five European centers located in Spain, France, and Germany. After providing written informed consent, patients are randomly assigned to either the control or intervention group, both of which undergo a six-week, intensive therapy regimen. The intervention group, which uses the Atalante X exoskeleton, engages in three weekly sessions, complemented by two conventional physiotherapy sessions. Each session lasts one hour. The control group receives five one-hour sessions of conventional physiotherapy per week, with no access to electromechanical devices dedicated to gait training during the study. At baseline, throughout the intervention period, at discharge and six months post-stroke, a blinded evaluator assesses the patients. Additionally, therapists are surveyed regarding the workload experienced during therapy sessions and patients are requested to provide self-assessments of their health-related quality of life. 
 
Hypothesis and Objectives: 
 
It is hypothesized that a higher proportion of patients will attain a FAC score of ≥ 4 upon completion of the intervention phase, indicating their ability to walk independently on level ground. The overall aim of this study is to test whether early and intensive walking therapy using the Atalante X exoskeleton leads to a superior recovery of functional walking compared to the control group, specifically in hemiparetic patients with limited or poor ambulatory capacities. Secondarily, various walking parameters, clinical evalu- ations of leg muscle strength, the subjective experiences of patients, and therapists reported outcomes, are recorded. 
 
Outlook: 
 
In the current recruitment phase, four patients have been enrolled in the German neurological rehabilitation centre Schoen Clinic Bad Aibling. We aim to gather a total sample size of 66 participants across the designated sites, emphasizing a meticulous recruitment process for a representative stroke population.

No comments:

Post a Comment